Buying guide
Apple Watch vs Stelo in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Apple | Dexcom |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $399-$799 (actual sale price) | $89-$99 (actual sale price) |
| Capability claims |
| — |
| Brain | — | — |
| Verified deployments | 1Apple | 1Dexcom |
| Privacy practices | 13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage | 4biometric-storage, training-data-use, third-party-sharing, data-deletion-control |
| Sources on file | 26 | 10 |
Editorial summaries
Apple Watch
The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features. Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.
Stelo
Dexcom's Stelo is the first-ever FDA-cleared over-the-counter (no-prescription) glucose biosensor (De Novo, March 5, 2024; US launch August 26, 2024): a 15-day continuous glucose monitor for adults 18+ not on insulin (type 2 not on insulin, plus non-diabetic users tracking how diet and exercise affect glucose). It is the generative-AI end of the glucose cell: Weekly Insights run on Google Cloud's Vertex AI and Gemini, with AI photo meal-logging and personalized daily recommendations, the AI substance that carries it across the biometric boundary. Pricing is about $89 for a 2-week sensor on a biweekly subscription model (around $99/month). From DexCom (NASDAQ: DXCM), Stelo is the OTC product line, separate from the prescription G7. Cap-flag: the cleared indication is an OTC CGM for adults 18+ not on insulin; it is explicitly NOT cleared for problematic hypoglycemia and has no low-glucose alerts, so it should not be read as a diabetes-management device.
Machine-readable: this page as markdown.